Back
Akari Therapeutics PLC 10K Form
Sell
27
AKTX
Akari Therapeutics PLC
Last Price:
2.27
Seasonality Move:
-8%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2016-05-12 | 10Q | AKTX/Akari Therapeutics PLC Quarterly |
2016-03-23 | 10K | AKTX/Akari Therapeutics PLC Annual |
2015-11-23 | 10Q | AKTX/Akari Therapeutics PLC Quarterly |
2015-08-12 | 10Q | AKTX/Akari Therapeutics PLC Quarterly |
2015-05-12 | 10Q | AKTX/Akari Therapeutics PLC Quarterly |
2015-02-11 | 10K | AKTX/Akari Therapeutics PLC Annual |
Receive AKTX News And Ratings
See the #1 stock for the next 7 days that we like better than AKTX
AKTX Financial Statistics
Sales & Book Value
Annual Sales: | $0 |
---|---|
Cash Flow: | $-4.89M |
Price / Cash Flow: | 0 |
Annual Sales: | $-0.30 |
Price / Book: | 0 |
Profitability
EPS (TTM): | -2.15650 |
---|---|
Net Income (TTM): | $-16.12M |
Gross Margin: | $0 |
Return on Equity: | 0% |
Return on Assets: | 0% |
Akari Therapeutics PLC Earnings Forecast
Key Akari Therapeutics PLC Financial Ratios
- The Interest Expense is 0.00% of Operating Income.
- Per Share Earnings over the last 14 years have been positive in 7 years.
Akari Therapeutics PLC Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | AKTX |
CUSIP: | 00972G |
Website: | akaritx.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
AKTX Technical Analysis vs Fundamental Analysis
Sell
27
Akari Therapeutics PLC (AKTX)
is a Sell
Is Akari Therapeutics PLC a Buy or a Sell?
-
Akari Therapeutics PLC stock is rated a Sell
The current Akari Therapeutics PLC [AKTX] share price is $2.30. The Score for AKTX is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.